New salmeterol/fluticasone dry powder inhaler for COPD

AirFluSal Forspiro (salmeterol/fluticasone) can be prescribed for adults with COPD who have a pre-bronchodilator FEV1 that is less than 60% of the predicted normal.

AirFluSal Forspiro is a breath-actuated dry powder inhaler containing the long-acting beta agonist salmeterol and the corticosteroid fluticasone.
AirFluSal Forspiro is a breath-actuated dry powder inhaler containing the long-acting beta agonist salmeterol and the corticosteroid fluticasone.

AirFluSal Forspiro contains 50 microgram salmeterol and 500 microgram fluticasone propionate, making its active ingredients and pre-dispensed dose identical to Seretide 500 Accuhaler. One inhalation is taken twice daily.

The inhaler is indicated for use in patients from 18 years of age with a history of repeated exacerbations and significant symptoms despite regular bronchodilator therapy.

Further information
View AirFluSal Forspiro drug record 
Summary of Product Characteristics
Manufacturer: Sandoz

AirFluSal Forspiro contains 60 doses of medication in pre-dispensed blisters on a coiled strip of foil. A lever is lifted to move a new blister into position, and then pressed to pierce the blister. Used blisters can then be torn off. The dose counter counts down from 60 to 0 with the last 10 doses appearing on a red background. 

Equivalence study

The equivalence study used to support approval of AirFluSal Forspiro was conducted outside the licensed COPD indication, in 555 patients with asthma. Results showed there was no significant difference in FEV1 increases over 12 weeks between patients using AirFluSal Forspiro and those using Seretide 500 Accuhaler. Asthma symptom scores improved to a similar extent in the two groups and the proportion of patients with controlled asthma was comparable between groups. 

Safety profiles were similar for the two devices.

Updated 11th March 2016


Previous versions of this article included the statement "Equivalence to Seretide Accuhaler was shown in patients with asthma". This sentence has been revised to emphasise that the inclusion of asthma patients in the equivalence study was outside the licensed indication of AirFluSal Forspiro in COPD. AirFluSal Forspiro is not indicated for use in asthma.


Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases